Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Buy” from Analysts

Alumis Inc. (NASDAQ:ALMS) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $26.00.

Several equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective (down from $19.00) on shares of Alumis in a report on Thursday. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday. Finally, Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective for the company.

Institutional Trading of Alumis

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in shares of Alumis in the third quarter valued at approximately $27,000. Wells Fargo & Company MN increased its stake in Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after acquiring an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Alumis in the 4th quarter valued at $79,000. MetLife Investment Management LLC bought a new stake in shares of Alumis during the 3rd quarter valued at $89,000. Finally, Marshall Wace LLP acquired a new stake in shares of Alumis during the 4th quarter worth $108,000.

Alumis Price Performance

ALMS stock opened at $3.57 on Friday. Alumis has a 1-year low of $3.52 and a 1-year high of $13.53. The business’s 50 day simple moving average is $5.76 and its 200 day simple moving average is $8.65.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.